- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | TETRATHERIX LIMITED: Director Company Secretary Appointment/Resignation | - | ASX | ||
| 08.12. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | - | ASX | ||
| 30.11. | TETRATHERIX LIMITED: BioOptix Alcon Update | 1 | ASX | ||
| 20.11. | TETRATHERIX LIMITED: Notice of Escrow Release | - | ASX | ||
| 10.11. | TETRATHERIX LIMITED: Results of Annual General Meeting | 1 | ASX | ||
| TETRATHERIX Aktie jetzt für 0€ handeln | |||||
| 09.11. | TETRATHERIX LIMITED: 2025 AGM Chair and CEO Address | - | ASX | ||
| 26.10. | TETRATHERIX LIMITED: Q1FY26 Quarterly Activities Report/Appendix 4C | - | ASX | ||
| 13.10. | TETRATHERIX LIMITED: Tutela Update | - | ASX | ||
| 09.10. | TETRATHERIX LIMITED: 2025 Notice of Annual General Meeting | - | ASX | ||
| 08.09. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | 4 | ASX | ||
| 05.09. | TETRATHERIX LIMITED: Application for quotation of securities - TTX | - | ASX | ||
| 29.08. | TETRATHERIX LIMITED: Notice of Escrow Release | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: 2025 Financial Results Investor Webinar | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: 2025 Financial Results Investor Presentation | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: 2025 Financial Results Announcement | - | ASX | ||
| 28.08. | TETRATHERIX LIMITED: Appendix 4E and 2025 Annual Report | - | ASX | ||
| 21.08. | TETRATHERIX LIMITED: Notification regarding unquoted securities - TTX | - | ASX | ||
| 14.08. | Recent ASX debutant Tetratherix locks in A$3.3M gov't grant for healtech | 3 | The Market Herald Australia | ||
| 14.08. | TETRATHERIX LIMITED: Australian Government grant to co-fund strategic program | 1 | ASX |
1 2 3 Weiter >>
51 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 4,765 | +13,45 % | Recursion jumps as J.P. Morgan upgrades on lead program | ||
| QIAGEN | 38,480 | +1,29 % | QIAGEN NV steht still - für mich ist das kein Stillstand! | ||
| IMMUNOME | 20,600 | -11,93 % | Immunome-Aktie fällt nach Ankündigung einer Kapitalerhöhung über 400 Mio. US-Dollar | ||
| AVIDITY BIOSCIENCES | 71,87 | -0,14 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| KYVERNA THERAPEUTICS | 7,170 | -30,05 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock | EMERYVILLE, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients... ► Artikel lesen | |
| BIONTECH | 78,00 | -0,64 % | 60 Prozent Aufwärtspotenzial?: BioNTech: Diese Gamechanger sind noch nicht im Kurs eingepreist! | © Foto: Sebastian Gollnow/dpa Für Anleger von BioNTech gab es 2025 nicht viel zu feiern. Auf Jahressicht hat die Aktie rund 15 Prozent verloren. Dabei sind die großen Innovationen im Krebsbereich noch... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 61,31 | -0,60 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 267,12 | -2,79 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 32,720 | -4,47 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| KYMERA THERAPEUTICS | 81,33 | -3,32 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| VOR BIOPHARMA | 14,380 | -9,27 % | Vor Biopharma: TD Cowen startet mit Kaufempfehlung und verweist auf Telitacicept-Potenzial | ||
| MINERALYS THERAPEUTICS | 37,470 | +4,05 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,940 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,240 | +0,06 % | Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development | ||
| IMMUNOVANT | 26,790 | +0,60 % | Immunovant: 550-Millionen-Dollar-Kapitalerhöhung und neue Studiendetails |
TETRATHERIX LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TETRATHERIX LIMITED finden Sie auf Wallstreet Online.